Preclinical Data Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Preclinical Data

Health Care Term

Preclinical data refers to the data generated during the early stages of drug development before human testing. It includes information about the pharmacology (the study of how drugs affect the body), pharmacokinetics (the study of how drugs move through the body), toxicity, and efficacy of the drug. Preclinical data is collected from in vitro (cell) and in vivo (animal) studies.

In the health care industry, preclinical data is essential as it provides important information about the safety and effectiveness of drug candidates. This information is used to determine which drugs should move forward into human clinical trials. Preclinical data helps drug developers to identify potential safety concerns and to optimize drug dosing regimens. It also provides insight into the mechanism of action of the drug, which can be used to guide drug development.

Preclinical data is also important in the regulatory approval process. Regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, use preclinical data to evaluate the safety and efficacy of drug candidates. The FDA requires robust preclinical data before approving a drug for human clinical trials.

Overall, preclinical data plays a critical role in the drug development process and is essential for ensuring the safety and efficacy of new drugs.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P